Bothrops Jararaca Snake Venom Modulates Key Cancer-Related Proteins in Breast Tumor Cell Lines
Total Page:16
File Type:pdf, Size:1020Kb
toxins Article Bothrops Jararaca Snake Venom Modulates Key Cancer-Related Proteins in Breast Tumor Cell Lines Carolina Yukiko Kisaki 1, Stephanie Santos Suehiro Arcos 1, Fabio Montoni 1, Wellington da Silva Santos 1, Hamida Macêdo Calacina 1, Ismael Feitosa Lima 1, Daniela Cajado-Carvalho 1 , Emer Suavinho Ferro 2 , Milton Yutaka Nishiyama-Jr 1,* and Leo Kei Iwai 1,* 1 Laboratory of Applied Toxinology (LETA) and Center of Toxins, Immune-Response and Cell Signaling (CeTICS), Butantan Institute, São Paulo 05503-900, Brazil; [email protected] (C.Y.K.); [email protected] (S.S.S.A.); [email protected] (F.M.); [email protected] (W.d.S.S.); [email protected] (H.M.C.); [email protected] (I.F.L.); [email protected] (D.C.-C.) 2 Department of Pharmacology, Biomedical Sciences Institute (ICB), University of São Paulo (USP), São Paulo 05508-000, Brazil; [email protected] * Correspondence: [email protected] (M.Y.N.-J.); [email protected] (L.K.I.) Abstract: Cancer is characterized by the development of abnormal cells that divide in an uncontrolled way and may spread into other tissues where they may infiltrate and destroy normal body tissue. Several previous reports have described biochemical anti-tumorigenic properties of crude snake venom or its components, including their capability of inhibiting cell proliferation and promoting cell death. However, to the best of our knowledge, there is no work describing cancer cell pro- teomic changes following treatment with snake venoms. In this work we describe the quantitative changes in proteomics of MCF7 and MDA-MB-231 breast tumor cell lines following treatment with Citation: Kisaki, C.Y.; Arcos, S.S.S.; Bothrops jararaca snake venom, as well as the functional implications of the proteomic changes. Cell Montoni, F.; da Silva Santos, W.; lines were treated with sub-toxic doses at either 0.63 µg/mL (low) or 2.5 µg/mL (high) of B. jararaca Calacina, H.M.; Lima, I.F.; venom for 24 h, conditions that cause no cell death per se. Proteomics analysis was conducted Cajado-Carvalho, D.; Ferro, E.S.; on a nano-scale liquid chromatography coupled on-line with mass spectrometry (nLC-MS/MS). Nishiyama-Jr, M.Y.; Iwai, L.K. More than 1000 proteins were identified and evaluated from each cell line treated with either the Bothrops Jararaca Snake Venom low or high dose of the snake venom. Protein profiling upon venom treatment showed differential Modulates Key Cancer-Related Proteins in Breast Tumor Cell Lines. expression of several proteins related to cancer cell metabolism, immune response, and inflammation. Toxins 2021, 13, 519. https://doi.org/ Among the identified proteins we highlight histone H3, SNX3, HEL-S-156an, MTCH2, RPS, MCC2, 10.3390/toxins13080519 IGF2BP1, and GSTM3. These data suggest that sub-toxic doses of B. jararaca venom have potential to modulate cancer-development related protein targets in cancer cells. This work illustrates a novel Received: 5 July 2021 biochemical strategy to identify therapeutic targets against cancer cell growth and survival. Accepted: 19 July 2021 Published: 25 July 2021 Keywords: mass spectrometry; proteome; snake venom; Bothrops jararaca; breast cancer Publisher’s Note: MDPI stays neutral Key Contribution: We describe that B. jararaca snake venom modulates specific protein pathways with regard to jurisdictional claims in related to cancer cell growth and invasion, which could be a useful approach to identify novel published maps and institutional affil- therapeutic targets for cancer treatment. iations. 1. Introduction Copyright: © 2021 by the authors. Ophidian accidents constitute a serious public health problem in Brazil, with an av- Licensee MDPI, Basel, Switzerland. erage of 29,000 cases and 125 deaths reported every year (Brazilian Ministry of Health, This article is an open access article 2019) [1]. Approximately 80% of ophidian accidents are caused by snakes of the Viperidae distributed under the terms and family, more specifically of the Bothrops genus [2]. Among them, about 25% lead to death conditions of the Creative Commons or sequels capable of generating temporary or permanent incapacity for work and custom- Attribution (CC BY) license (https:// ary activities. Venom from the Bothrops jararaca (B. jararaca) snake is a complex mixture creativecommons.org/licenses/by/ 4.0/). composed of proteins, peptides, amino acids, nucleotides, lipids, and carbohydrates that Toxins 2021, 13, 519. https://doi.org/10.3390/toxins13080519 https://www.mdpi.com/journal/toxins Toxins 2021, 13, 519 2 of 28 present a range of different actions when they are isolated or together [3–7], leading to hemotoxic, cardiotoxic, cytotoxic, or neurotoxic effects [8,9]. Several previous reports have defined the proteomics composition of Bothrops venoms [5,10–16]. These studies have shown that Bothrops venoms are composed of various classes of toxin, including metalloproteinases, serine proteinases, phospholipases A2, and C-type lectins, the most abundant components participating in the local and systemic envenomation effects. The venom of B. jararaca engenders three main activities: proteolytic, coagulant, and hemolytic. The proteolytic activity causes degradation of extracellular matrix proteins, plasma, and cell surface [17], which represents an important factor for the clinical charac- terization of a bothropic accident [2,18]. In addition, venom can cause local tissue lesion, myonecrosis, edema, cardiovascular alterations, hypovolemic shock, coagulation alteration and renal alterations, resulting from the combined action of the enzymatic and toxic ac- tivity of the venom [19]. About 90 to 95% of the dry weight of the B. jararaca venom is composed of a complex mixture of proteins, mainly metalloproteinases, serine proteinases, phospholipases (PLA2), and L-amino acid oxidases. The metalloproteinases comprise most of the venom composition [20,21]. They are proteolytic enzymes associated with fibrinolysis and coagulation, and they are involved in cell migration and tissue repair, besides being related to pathological effects such as cancer [22,23]. In terms of therapeutic interventions, protease inhibitors have been shown to inhibit homeostasis and thrombosis by acting on the coagulation cascade [24]. The third major component of the venom, PLA2, is an enzyme capable of hydrolyzing the ester bonds at the sn2 position of glycerolphos- pholipids, releasing arachidonic acid, important for the biosynthesis of many mediators involved in inflammation, such as prostaglandins, thromboxanes, and leukotrienes [25]. Finally, the L-amino acid oxidases (LAAOs), which make up about 1 to 9% of the venom composition [26], are flavoenzymes belonging to the class of oxidoreductases, which pro- duce alpha-keto acid, hydrogen peroxide, and ammonia [27,28]. However, when there is a high production of hydrogen peroxide, it has been found that L-amino acid oxidases can induce apoptosis in mammalian endothelial cells [29]. Snake venom constituents have been isolated and studied for their therapeutic poten- tial in the treatment of various diseases. One example is Eptifibatide, marketed as Integrilin, derived from the Echis carinatus snake venom and produced by Millennium Pharmaceu- ticals and Schering-Plow. It is used as an antiplatelet drug [30]. Another example is the angiotensin I converting enzyme inhibitor Captopril produced by Bristol-Myers Squibb whose active component was derived from B. jararaca venom. It is used for the treatment against hypertension and renal insufficiency [31,32]. In addition to the potential use of the derivatives of snake venom toxins in the treatment of non-malignant diseases [33], several studies have described anti-tumorigenic characteristics of snake venom, stating that snake venom may be capable of inhibiting cell proliferation and promoting cell death by different means: inducing apoptosis in cancer cells by increasing the influx of Ca2+, inducing the release of cytochrome C, decreasing or increasing the expression of proteins that control the cell cycle, and causing damage to cell membranes [26,34–36]. With the goal of searching novel therapy against cancer, studies have characterized the proteins, peptides or enzymes derived from snake venom to identify components that are capable of interfering with the transport of substances or signal transduction across the membrane or disrupting the cell membrane [35,37]. With the rapid advances of nano-scale liquid chromatography (nLC) and mass spec- trometry (MS) technologies in the last two decades, nLC-MS/MS-based proteomics analysis has been widely applied as a powerful tool for biomarker discovery to improve cancer therapy [38,39]. A number of studies have characterized the biochemical and physiological action of venom or isolated venom derivatives on cell lines or tissues [40–43]. In addition, several works have shown proteomic changes of cancer cell lines upon drug treatment that suggest molecular mechanisms of drug action, including diverse effects on proteasome regulation, metabolic processes, and oxidative stress [44,45]. Toxins 2021, 13, x FOR PEER REVIEW 3 of 28 43]. In addition, several works have shown proteomic changes of cancer cell lines upon Toxins 2021, 13, 519 drug treatment that suggest molecular mechanisms of drug action, including diverse3 of 28 effects on proteasome regulation, metabolic processes, and oxidative stress [44,45]. However, to the best of our knowledge, there has been no report that describes the effects of B. jararaca snake venom treatment on breast cancer-related cell proteome. In the However, to the best of our knowledge, there has been no report that describes the present study, nLC-MS/MS was used to characterize the effects of sub-toxic doses of B. effects of B. jararaca snake venom treatment on breast cancer-related cell proteome. In jararaca snake venom on two different breast cancer cell lines MCF7 and MDA-MB-231. the present study, nLC-MS/MS was used to characterize the effects of sub-toxic doses of MCF7 and MDA-MB-231 are non-metastatic and metastatic tumor cell lines, respectively. B. jararaca snake venom on two different breast cancer cell lines MCF7 and MDA-MB-231.